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Abstract
Introduction Evidence suggests that citrullinated fibrin(ogen)
may be a potential in vivo target of anticitrullinated protein/
peptide antibodies (ACPA) in rheumatoid arthritis (RA). We
compared the diagnostic yield of three enzyme-linked
immunosorbent assay (ELISA) tests by using chimeric fibrin/
filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2,
CFFCP3) with a commercial CCP2-based test in RA and
analyzed their prognostic values in early RA.
Methods Samples from 307 blood donors and patients with RA
(322), psoriatic arthritis (133), systemic lupus erythematosus
(119), and hepatitis C infection (84) were assayed by using
CFFCP- and CCP2-based tests. Autoantibodies also were
analyzed at baseline and during a 2-year follow-up in 98 early RA
patients to determine their prognostic value.
Results With cutoffs giving 98% specificity for RA versus blood
donors, the sensitivity was 72.1% for CFFCP1, 78.0% for
CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with
positive predictive values greater than 97% in all cases. CFFCP
sensitivity in RA increased to 80.4% without losing specificity
when positivity was considered as any positive anti-CFFCP
status. Specificity of the three CFFCP tests versus other
rheumatic populations was high (> 90%) and similar to those for
the CCP2. In early RA, CFFCP1 best identified patients with a
poor radiographic outcome. Radiographic progression was
faster in the small subgroup of CCP2-negative and CFFCP1-
positive patients than in those negative for both autoantibodies.
CFFCP antibodies decreased after 1 year, but without any
correlation with changes in disease activity.
Conclusions CFFCP-based assays are highly sensitive and
specific for RA. Early RA patients with anti-CFFCP1 antibodies,
including CCP2-negative patients, show greater radiographic
progression.
Introduction
Anti-citrullinated protein/peptide antibodies (ACPAs) are con-
sidered the most specific serologic markers of rheumatoid
arthritis (RA) [1]. Although the sensitivity is similar to that of
rheumatoid factor (RF)--the only antibody included in the
American College of Rheumatology (ACR) classification crite-
ACPA: anti-citrullinated protein/peptide antibodies; ACR: American College of Rheumatology; Arg: arginine; CCP1: cyclic citrullinated first-genera-
tion peptide assay; CCP2: cyclic citrullinated second-generation peptide assay; CCP3: cyclic citrullinated third-generation peptide assay; CFFCP1: 
chimeric fibrin/filaggrin citrullinated peptides 1; CFFCP2: synthetic chimeric fibrin/filaggrin peptides 2; CFFCP3: synthetic chimeric fibrin/filaggrin 
peptides 3; Cit: citrulline residue; DAS28: disease activity score in 28 joints; DMARDs: disease-modifying antirheumatic drugs; ELISAs: enzyme-
linked immunosorbent assays; HCV: hepatitis C virus; mHAQ: modified Health Assessment Questionnaire; NPV: negative predictive value; PPV: pos-
itive predictive value; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RF: rheumatoid factor; SLE: systemic lupus erythematosus; TNF: tumor necrosis 
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ria--ACPAs have a higher specificity [2]. ACPAs recognize
proteins or peptides with arginine residues converted to citrul-
line by a posttranslational modification and have diagnostic
and prognostic significance [3]. Recent studies have demon-
strated that ACPAs are the strongest serum marker associ-
ated with future RA progression in patients with recent-onset
arthritis [4,5] and radiographic progression in ACPA-positive
patients with early RA is greater than that in ACPA-negative
patients [6-8]. ACPAs also have been linked to certain genetic
and epidemiologic characteristics such as the HLADRB04
genotype [9] and smoking [10].
ACPAs can be detected by using enzyme-linked immunosorb-
ent assays (ELISAs) with different citrullinated protein or pep-
tide substrates. The most widely used in clinical practice is the
cyclic citrullinated peptide 2 assay (CCP2) [1-3]. The cyclic
peptide(s) in the CCP2 have no homology with known pro-
teins [1] and improved the sensitivity of the first test to become
available based on a synthetic citrullinated peptide derived
from filaggrin (CCP1) [11]. More recently, other ELISA tests
using citrullinated mutated vimentin [12], citrullinated human
fibrinogen [13], or third-generation citrullinated peptides
(CCP3) [14] with useful diagnostic and prognostic properties
have been developed. Although most ACPA-based tests
seem to have similar diagnostic yields, discrepancies may
arise, probably because of the different antigen sources used
[15].
Although original assays used citrullinated peptides derived
from human filaggrin, this epithelial protein is not expressed in
synovial tissues and so is probably not the in vivo target of
these autoantibodies. Several proteins present in inflamed
rheumatoid synovium, such as type I collagen, vimentin, -eno-
lase, and fibrin(ogen), can be citrullinated [16]. Citrullinated
fibrin has been identified as a potential synovial target for
ACPA [17], and two citrullinated fibrin-derived peptides in the
 and  chains of human fibrin have been found to be the main
antigen substrates for these antibodies [18]. We previously
demonstrated the special ability and specificity of a citrulli-
nated peptide sequence of -fibrin ([Cit621,627,630]-
fibrin(617-631)) to recognize autoantibodies in RA sera [19].
Three cyclic citrullinated peptides derived from these regions
of -fibrin were found to recognize serum autoantibodies in
RA in a subsequent study [20]. Further interesting results
were obtained with a chimeric fibrin/filaggrin citrullinated pep-
tide (CFFCP1) containing an -fibrin peptide and the cyclic
filaggrin peptide, cfc-1cyc, which forms the basis of the com-
mercial CCP1 test. The noncommercial ELISA test using this
chimeric citrullinated synthetic peptide was more sensitive
than the commercial one using CCP1 (82% vs. 65.8%) in an
RA population and reacted with some CCP2-negative sera
[20].
The aim of the present study was to evaluate the diagnostic
yield of three ELISA tests based on this CFFCP1 peptide and
two new synthetic chimeric fibrin/filaggrin peptides (CFFCP2,
CFFCP3) and to compare their sensitivity and specificity in RA
and other disease groups with the commercial CCP2 test. The
prognostic value of these chimeric ACPAs also was studied in
a cohort of patients with early RA.
Materials and methods
Diagnostic yield
Patients
The study included five different populations. The adult RA
population comprised 322 patients, all of whom fulfilled the
1987 ACR classification criteria. Of these, 70.4% were posi-
tive for RF, and 134 had early RA (< 2 years of disease dura-
tion). Seventy-eight patients were receiving biologic therapy
(tumor necrosis factor (TNF)- antagonist) at the time of sero-
logic determination. Four different control groups were
included: 307 healthy blood donors, 119 patients with sys-
temic lupus erythematosus (SLE) according to ACR criteria,
133 patients with psoriatic arthritis (PsA) fulfilling the Wright
and Moll criteria, and 84 patients with chronic hepatitis C virus
(HCV) infection (confirmed by nucleic acid testing and anti-
body test results).
Prognostic value
Patients
All 134 patients with early RA from the study of diagnostic
value were included in a prospective study of prognostic fac-
tors in early RA. Two years of follow-up data were available for
98 of 134 patients. Results for radiographic and clinical evo-
lution in this early RA population have been published else-
where [21,22]. All were outpatients attending the
rheumatology departments of the Hospital Clínic of Barcelona
or the Hospital Parc Taulí of Sabadell, Spain.
Study design and follow-up
All patients were treated according to a therapeutic protocol
by using a step-up approach with early introduction of
DMARDs together with very low doses of glucocorticoids
(methylprednisolone, 4 mg/day) [21,22]. After the first year of
therapy, patients were treated according to the criteria of the
attending physician, but with an aggressive approach; other
DMARDs were added when the response to previous
DMARDs was poor. Biologic therapy was started in a few
patients with a poor response to DMARD therapy. Demo-
graphic characteristics and disease duration were recorded at
study entry. At baseline and at 6, 12, 18, and 24 months, dis-
ease activity was measured by using the index of disease
activity score in 28 joints (DAS28) [23], and disability, by
using the modified Health Assessment Questionnaire (mHAQ)
[24]. Serum rheumatoid factor (RF) was measured with neph-
elometry (BNII, Siemens; normal values, < 25 UI/ml). Radio-
graphs of hands and feet were taken at 0, 12, and 24 months.
The modified Larsen method [25] was used to evaluate radio-
graphic damage, as previously described [21]. Each partici-
pant signed a written informed consent. Both studies wereAvailable online http://arthritis-research.com/content/11/5/R135
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approved by the Ethics Committee of the Hospital Clinic of
Barcelona.
Chimeric fibrin/filaggrin synthetic peptides
The following chimeric -fibrin-filaggrin citrullinated peptides
were synthesized:
CFFCP1: [Cit630]fibrin(617-631)-S306,  S319cyclo
[Cys306,319, Cit312]filaggrin(304-324)
CFFCP2: [Cit627,630]fibrin(617-631)-S306,  S319cyclo
[Cys306,319, Cit312]filaggrin(304-324)
CFFCP3: [Cit621,630]fibrin(617-631)-S306,  S319cyclo
[Cys306,319, Cit312]filaggrin(304-324)
The chimeric linear sequences were synthesized in the solid
phase with subsequent cyclization in solution by forming a
disulfide bridge, as previously described for CFFCP1 [20].
Crude peptides were purified with preparative high-perform-
ance liquid chromatography (HPLC). The identity of the puri-
fied peptides was confirmed with electrospray mass
spectrometry, and their purity was determined with analytic
HPLC. The overall yield from peptide resins was 30% to 45%.
ELISA
Peptide sequences were coupled covalently to ELISA micro-
titer plates (Costar Corp., Cambridge, MA) as described pre-
viously [20]. All sera were tested in duplicate. Control sera
were also included to monitor inter- and intraassay variations.
Sera also were analyzed by using second-generation CCP2-
based ELISA (Immunoscan, Eurodiagnostica, distributed by
Diasorin Madrid, Spain). For patients included in the prognos-
tic analysis, serum samples were obtained at baseline and
after 1 and 2 years.
Statistical methods
Cutoff values for chimeric and commercial ELISA tests were
selected with ROC analysis to give a specificity of 98% for RA
versus healthy blood donors. The association between cate-
gorized anti-citrullinated antibodies and other qualitative varia-
bles was tested by using the 2 test and Fisher's Exact test, as
applicable. Sensitivity, specificity, and positive and negative
predictive values (PPVs and NPVs) of the ELISA tests were
calculated. To analyze anti-CFFCP and anti-CCP2 status with
relevant quantitative variables, the t test and analysis of vari-
ance were used unless conditions for such tests were not met,
in which case the Mann-Whitney U and Kruskal-Wallis tests
were used. Changes from baseline of the different autoanti-
bodies titers after 1 and 2 years of follow-up were analyzed by
using the t test for paired samples. The correlation between
different citrullinated peptide antibodies and the association
between antibody values and quantitative clinical variables
were tested with Pearson's correlation or Spearman's rank
correlation, as applicable. Comparison and analysis of ROC
curves were performed with MedCalc v7.6 software. Statisti-
cal analyses were performed by using SPSS 16.0. All P values
were two sided, and P < 0.05 was considered statistically sig-
nificant.
Results
Diagnostic value of anti-CFFCP antibodies
For the different ELISA tests investigated in this study, the area
under the ROC curves (RA vs. healthy blood donors) was not
significantly different: CFFCP1, 0.926 (95% CI, 0.905-
0.947); CFFCP2, 0.953 (95% CI, 0.938-0.969); CFFCP3,
0.925 (95% CI, 0.903-0.947), and CCP2, 0.940 (95% CI,
0.921-0.959). Cutoff values for each ELISA test calculated
according this ROC curve analysis were CFFCP1, 0.241
optic density units (ODUs); CFFCP2, 0.229 ODUs; CFFCP3,
0.280 ODUs; and CCP2, 30 IU/L. For cutoff values giving a
specificity of 98% with respect to blood donors, the sensitivity
of the noncommercial ELISAs was 72.1% for CFFCP1, 78%
for CFFCP2, and 71.4% for CFFCP3, with the PPV greater
than 97% in all three tests and the NPV between 76.7% and
80.9%. Similar results were obtained by using the commercial
CCP2 test (sensitivity, 73.9%; PPV, 97.6%; and NPV,
78.2%). The sensitivity of the three CFFCP tests was signifi-
cantly lower in RF-negative RA compared with RF-positive RA
(Table 1). As expected, serum titers of all citrullinated peptide
antibodies were higher in RF-positive RA compared with RF-
negative RA. However, patients with citrullinated peptide anti-
body titers above cutoff showed no differences in mean serum
levels between RF+ and RF- RA patients.
No significant differences in sensitivity were found between
the different assays according to the RA population studied
(Table 1). In the control populations, positive results were
observed in only a small proportion of patients in each type of
ELISA test (Figure 1), and these patients had low levels (Table
2). In the SLE group, positive results were observed in 7.6%
to 9.2% of sera in the CFFCP tests and commercial CCP2
tests. Most patients with SLE and positive ELISA tests had
antibody titers just above normal. In the PsA and HCV groups,
fewer than 4.5% of patients had positive anti-CFFCP or anti-
CCP2 status, except for anti-CFFCP2 status in PsA (9.8%)
and anti-CFFCP1 status in HCV (14.3%).
A very good correlation between the three types of CFFCP
test was observed in RA (R values between 0.96 and 0.98; P
< 0.0001), and a good correlation also was observed between
CFFCP tests and the CCP2 test (R values between 0.87 and
0.89; P < 0.0001), although discrepancies were observed in
some RA sera. Positive results with CFFCP1, CFFCP2, and
CFFCP3 were observed in 14.3%, 27.4%, and 9.5% of sera
from anti-CCP2-negative patients, respectively, and anti-
CCP2-positive status was observed in 20%, 28.9%, and
13.9% of patients negative for anti-CFFCP1, CFFCP2, and
CFFCP3, respectively. In 1.9% of sera, anti-CCP2 status wasArthritis Research & Therapy    Vol 11 No 5    Sanmartí et al.
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Table 1
Sensitivity of commercial CCP2 test and noncommercial CFFCP enzyme-linked immunosorbent assays in different rheumatoid 
arthritis populations and control groups
Population n CFFCP1 CFFCP2 CFFCP3 CCP2
Rheumatoid arthritis 322 232 (72%) 251 (78%) 230 (71.4%) 238 (73.9%)
RF+ 226 188 (83.2%) 199 (88.1%) 192 (85%) 199 (88.1%)
RF-a 95 43 (45.3%) 52 (54.7%) 38 (40%) 39 (41.1%)
Early 134 102 (76.1%) 104 (77.6%) 99 (73.9%) 99 (73.9%)
Anti-TNF- treatment 78 56 (71.8%) 62 (79.5%) 61 (78.2%) 62 (79.5%)
Healthy blood donors 307 6 (2%) 6 (2%) 6 (2%) 6 (2%)
Systemic lupus erythematosus 119 11 (9.2%) 11 (9.2%) 9 (7.6%) 9 (7.6%)
Psoriatic arthritis 133 6 (4.5%) 13 (9.8%) 2 (1.5%) 4 (3%)
Hepatitis C virus infection 84 12 (14.3%) 2 (2.4%) 2 (2.4%) 1 (1.2%)
aP < 0.0001 for all autoantibodies in comparison with RF+ rheumatoid arthritis. In one RA patient, RF status was not available. RF = rheumatoid 
factor; TNF = tumor necrosis factor.
Figure 1
Titers of autoantibodies against the chimeric citrullinated fibrin/filaggrin peptides anti-CFFCP1, anti-CFFCP2, anti-CFFCP3, and against cyclic cit- rullinated peptide CCP2 in RA and control populations Titers of autoantibodies against the chimeric citrullinated fibrin/filaggrin peptides anti-CFFCP1, anti-CFFCP2, anti-CFFCP3, and against cyclic cit-
rullinated peptide CCP2 in RA and control populations. Boxes represent interquartile range and median. Whiskers represent values outside the 
interquartile range. Single points represent outliers and extreme values. RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; HCV = 
hepatitis C virus infection; PsA = psoriatic arthritis; BD = blood donor.Available online http://arthritis-research.com/content/11/5/R135
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positive, although anti-CFFCP status was negative. In addi-
tion, 1.9% of patients positive in the three CFFCP tests were
negative with CCP2 ELISA. Discrepant cases tended to be
associated with near-normal serum titers. When positivity was
considered as one or more positive anti-CFFCP status, sensi-
tivity increased to 80.4% whereas specificity remained high
(97.7%).
Prognostic value of anti-CFFCP antibodies
Demographic and clinical characteristics and disease 
course in the early RA population
At study entry, the mean age of the 98 patients (81.6%
women) with early RA was 54.6 ± 14.8 years, and the disease
duration was 9.1 ± 5.9 months. Rheumatoid factor was posi-
tive in 72.4% of patients. The mHAQ at baseline was 1 ± 0.5.
DAS28 decreased significantly from a mean of 5.72 ± 0.9 at
baseline to 3.72 ± 1.23 and 3.45 ± 1.23 at 1 and 2 years of
follow-up, respectively. Remission (DAS28 < 2.6) was
achieved by 23.7% and 30.9% of patients at month 12 and
24, respectively. The mean Larsen score progressed from 1.3
± 2.7 at study entry to 6.0 ± 9.4 at the end of follow-up.
Anti-CFFCP antibodies in early RA
Serum levels of the three anti-CFFCP antibodies and anti-
CCP2 antibodies were obtained at baseline in all 98 patients.
Positive anti-CFFCP1, anti-CFFCP2, and anti-CFFCP3 status
was reported in 70%, 73%, and 76% of patients, respectively,
and anti-CCP2 status, in 73%.
Serial serum measurements of the different autoantibodies
were made in the majority of patients at baseline and during
the follow-up. In 56 patients, all four tests were available at
baseline and at 1 and 2 years of follow-up. CFFCP status
remained stable in most patients during the follow-up, but
some patients became positive (2.3% to 12.8%) and even
more became negative (12.2% to 21.7%). Negative conver-
sion occurred mainly in patients with serum levels just above
the normal range for both the CCFCP test and the commercial
CCP2 test. Mean serum levels of the different anti-CFFCP and
anti-CCP2 antibodies tended to decrease during the follow-
up, although the difference was statistically significant only for
anti-CFFCP2 and anti-CCP2 status at 1 year (data not
shown).
Anti-CFFCP antibodies and disease activity
At baseline, disease activity measured by the DAS28 score
was similar in patients with and without anti-CFFCP1, anti-
CFFCP2, and anti-CFFCP3 antibodies and those with and
without anti-CCP2 antibodies. The DAS28 score decreased
significantly in positive and negative patients, but differences
were not significant at 1 and 2 years (Figure 2). No correlation
between the variations in anti-CFFCP antibody titers and dif-
ferent measures of disease activity at 1 and 2 years was found,
except in the case of anti-CFFCP3 titer and the swollen-joint
count at 2 years (P = 0.04). The change in DAS28 at 2 years
(P = 0.04) and change in the swollen-joint count at 1 and 2
years (P = 0.03 and P = 0.001) correlated with variations of
the CCP2 test at 2 years, but the correlations disappeared
after Bonferroni correction.
Anti-CFFCP antibodies and radiographic damage
Baseline radiographic damage measured by the Larsen score
was significantly higher in patients with CFFCP1 antibodies
than in those without. Higher scores were also observed in
patients with positive anti-CFFCP2, anti-CFFCP3, and anti-
CCP2 status than those with negative status, but these differ-
ences were not statistically significant. After 24 months, signif-
icantly higher Larsen scores were observed only for positive
anti-CFFCP1 status versus negative status, although a clear
nonsignificant trend was observed also for positive anti-CCP2
status (Figure 3). Mean Larsen scores at baseline and at 2
years were higher in the small group of patients negative for
anti-CCP2 antibodies and positive for anti-CFFCP1 antibod-
ies (n = 8; mean ± SD, 1.6 ± 2.2 and 6.4 ± 10.9, respectively)
than were those observed in patients negative for both autoan-
tibodies (n = 22; mean ± SD, 0.4 ± 1.2 and 3.0 ± 6.0, respec-
Table 2
Serum levels of anti-CFFCP and anti-CCP2 antibodies in the sera of RA and non-RA populations with values above the cut-off point
CFFCP1 CFFCP2 CFFCP3 CCP2
n No. positive Mean (Std) No. positive Mean (Std) No. positive Mean (Std) No. positive Mean (Std)
RA 322 232 1.58 (1) 251 1.61 (1.08) 230 1.70 (1.04) 238 842 (605)
SLE 119 11 0.73 (0.86) 11 0.78 (0.86) 9 0.95 (1.11) 9 205 (305)
HCV 84 12 0.34 (0.08) 2 0.66 (0.08) 2 0.41 (0.05) 1 46
PsA 133 6 0.52 (0.41) 13 0.39 (0.38) 2 1 (0.61) 4 120 (84)
BD 307 6 0.66 (0.45) 6 0.59 (0.45) 6 0.72 (0.52) 6 67 (37)
No = total number of patients; No. positive = number of positive patients; Std = standard deviation. Statistical differences were observed between 
RA and non-RA serum levels (P < 0.001).Arthritis Research & Therapy    Vol 11 No 5    Sanmartí et al.
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tively) and similar to those observed in patients positive for
both autoantibodies (n = 65; mean ± SD, 1.6 ± 3.1 and 7.0 ±
10.9, respectively).
Discussion
This study analyzed the diagnostic and prognostic properties
of three new ELISA tests for RA to detect ACPA. These non-
commercial assays, which use synthetic chimeric cyclic citrull-
inated peptides from filaggrin and the  chain of fibrin as
antigenic substrates, showed a high sensitivity and specificity
for RA in comparison with healthy controls and those with
other chronic diseases. Furthermore, in a group of early RA
patients, these antibodies were associated with poor radio-
graphic outcome.
Synovitis in RA is characterized by excessive generation and
breakdown of fibrinogen [26]. Citrullinated fibrinogen may par-
ticipate in the inflammatory process in RA, affecting the bal-
ance between coagulation and fibrinolysis [27] and acting as
an important autoantigen [28]. Recent data on the arthri-
togenic properties of citrullinated fibrinogen in a mouse model
of arthritis [29] and the presence of immune complexes con-
taining citrullinated fibrinogen in the sera and synovium of RA
point to a direct role in the pathogenesis of rheumatoid syno-
vitis [30]. An in vitro human model demonstrated the inflamma-
tory potential of ACPA-containing immune complexes of
citrullinated fibrin, inducing TNF- secretion by macrophages
[31]. Together, these findings reinforce the role of citrullinated
fibrinogen in RA pathogenesis and suggest that this protein
could be an important in vivo target of the ACPAs present in
RA sera and therefore an optimal antigenic substrate for the
determination of ACPAs.
We analyzed the sensitivity and specificity of CFFCP1 in a
large group of RA patients and other well-defined control
groups. We also included two new synthetic chimeric pep-
tides also derived from filaggrin and the  chain of fibrin
(CFFCP2 and CFFCP3). The ELISA assays for chimeric cit-
rullinated peptides showed a high sensitivity (71.4% to
78.0%) for RA diagnosis, similar to that seen for the CCP2-
based test (73.9%), by using cutoff values yielding 98% spe-
cificity with respect to healthy blood donors. The sensitivity of
CFFCP is similar in patients with early RA and in those with
established disease, and lower in RF-negative patients, as pre-
viously reported [32].
As expected, the specificity of anti-CFFCP antibodies was not
as high when compared with other chronic diseases, espe-
cially SLE, in which up to 9.2% of sera yielded positive results,
as observed in our population and in other studies [33,34].
Figure 2
Comparative changes in the disease-activity score DAS28 during the 2 years of follow-up in early RA patients who are positive and negative for anti- CFFCP and anti-CCP2 at baseline Comparative changes in the disease-activity score DAS28 during the 2 years of follow-up in early RA patients who are positive and negative for anti-
CFFCP and anti-CCP2 at baseline. Anti-CFFCP1 (n = 101), anti-CFFCP2 (n = 98), anti-CFFCP3 (n = 98), and anti-CCP2 (n = 109). Mean values 
are presented. *P < 0.05.Available online http://arthritis-research.com/content/11/5/R135
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However, antibody levels were low in most SLE patients with
positive results compared with RA patients. The different anti-
CFFCP antibodies were also detected in a small number of
patients with PsA or HCV infection.
As previously described by our group [19,20], not all citrulli-
nated fibrin-derived peptides are equally immunoreactive with
ACPA, reflecting the importance of the aminoacyl environment
of citrulline residues and the correct balance of Arg/Cit resi-
dues within the synthetic molecule. This probably influences
the adoption of a preferred conformation with enhanced
capacity for binding to autoantibodies present in RA patients.
Of all the -fibrin-related peptides we analyzed, those span-
ning the region from 617 to 631, with a citrullyl residue at the
630 position, were clearly the most reactive [20]. Thus, in
agreement with the results reported by Sebagg et al. [18], the
Cit630-bearing peptides from -fibrin could represent a good
molecular mimic of the ACPA epitopes targeted in vivo. Par-
ticularly good results were obtained by combining two peptide
units of different citrullinated proteins. In particular, CFFCP1,
CFFCP2, and CFFCP3, the three 15-mer Cit630-bearing pep-
tides from -fibrin covalently coupled to the cyclic filaggrin
peptide, which constitutes the CCP1 test [35], have been
shown to be the most reactive ACPA epitopes [20].
The CCP2-based test was very specific and highly sensitive
for RA, with a higher sensitivity than that of CCP1 [36]. Our
results showed a similar sensitivity, specificity, and predictive
values for the diagnosis of RA compared with the commercial
CCP2 test. A similar diagnostic yield was described for CCP2
and anti-citrullinated fibrinogen in a study with an ELISA test
containing human fibrinogen as the antigenic epitope [37]. A
very strong correlation was found between the three anti-
CFFCP antibodies and between anti-CFFCPs and anti-CCP2
antibodies, although a significant proportion of sera showed
discrepancies, mainly in patients with antibodies near the cut-
off values. Our studies also found discordant results when dif-
ferent commercial ELISA tests were compared, with the main
explanation being the different types of antigenic peptide/pro-
teins used [15,38]. The sensitivity of the presence of any of the
three anti-CFFCP antibodies increased to 80.5%, 6.6%
higher than the commercial CCP2-based test, with no loss of
specificity.
Studies have shown that ACPAs are associated with a poor
disease outcome. Most of these studies used the commercial
CCP1- or CCP2-based tests [6-8], but some also used anti-
bodies against citrullinated human fibrin(ogen) [13,39], and
mutated vimentin [12,40] has been associated with radio-
graphic damage. In our cohort with early RA, modified Larsen
scores at baseline and 2 years after starting DMARD therapy
were higher in patients with positive baseline values of anti-
CFFCPs, with significant differences at both time points for
anti-CFFCP1 antibodies. A clear but nonsignificant trend also
Figure 3
Radiographic progression (Larsen scores) and anti-CFFCP and anti-CCP2 status in patients with early RA after 2 years of follow-up Radiographic progression (Larsen scores) and anti-CFFCP and anti-CCP2 status in patients with early RA after 2 years of follow-up. *P < 0.01. **P 
< 0.05.Arthritis Research & Therapy    Vol 11 No 5    Sanmartí et al.
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was observed for anti-CFFCP2, anti-CFFCP3, and anti-CCP2
status. Patients with positive anti-CFFCP and negative anti-
CCP2 status had a radiographic progression similar to that
observed in patients positive for both autoantibodies, indicat-
ing that these autoantibodies may be a markers of poor radio-
graphic outcome in a subgroup of patients who are anti-CCP2
negative; however, the subgroups were too small to draw
definitive conclusions.
Despite radiographic progression, patients with and without
baseline anti-CFFCP antibodies and CCP2 followed a similar
clinical course, according to DAS28. Short follow-up could
explain why anti-CFFCP status at baseline does not correlate
with disease activity, because some studies found a more-
severe disease course in patients with ACPA, primarily after 2
years of follow-up [41,42].
As observed with anti-CCP2 antibodies [43] and antibodies
against mutated vimentin in early RA [40], reduced anti-
CFFCP antibody titers were observed in our cohort during the
follow-up. We found no correlation between changes in
CFFCP antibody titers and changes in most parameters of dis-
ease activity during follow-up. Our results are very similar to
those observed with anti-CCP2 antibodies in this and other
studies [42-44], but differ from those observed with anti-citrull-
inated vimentin antibodies, in which an association between
clinical improvement and change in antibody titers was
reported in early RA [40]. We do not know whether this
reflects different antibody properties or differences in treat-
ment strategies with DMARDs.
Conclusions
In conclusion, CFFCP antibodies have a high sensitivity and
specificity for RA when compared in a large series of patients
with various rheumatic conditions and healthy controls, with
results comparable to those obtained with the commercial
CCP2 test. Anti-CFFCP1 antibodies seem to give better
results than the other anti-CFFCPs and CCP2 antibodies in
terms of identifying patients with poor radiographic outcome.
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